Half-year liquidity contract statement for LYSOGENE

Half-year liquidity contract statement for LYSOGENE 150 150 Lysogene

Paris, France — 05 July 2021 at 06:00 pm CEST — Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today presents the half-year report on the liquidity contract signed by Lysogene with Kepler Cheuvreux.

Lysogene COVID-19 update

Get In Touch

Don’t hesitate to contact us if you need more help.

    Back to top